FY2025 · ended Dec 31, 2025 · Revenue $200,000, -41.5% YoY · Filed Mar 17, 2026
Clene Inc. (CLNN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $200,000 and a net loss of $26.2 million. Free cash flow was -$18.6 million. As of Sep 30, 2026 it held $9.9 million in cash and investments and $20.9 million in total debt.
Revenue (TTM)
$238,000
+11.2% vs year-ago TTM
Net income (TTM)
$-26.83M
+12.0% vs year-ago TTM
Operating cash flow (TTM)
$-16.53M
+11.2% vs year-ago TTM
Free cash flow (TTM)
$-16.61M
+10.8% vs year-ago TTM
EPS
—
Dividend per share
None
Shares outstanding
11.78M
+37.2% vs prior year
Net cash
$-11.02M
as of Sep 30, 2026
Operating margin
-8928.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CLNN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1822791
- Former names
- Chelsea Worldwide Inc. (until Dec 18, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $200,000 | $342,000 | $654,000 | $473,000 | $723,000 |
| Operating income | -$23.1M | -$33.1M | -$40.5M | -$48.4M | -$50.0M |
| Net income | -$26.2M | -$39.4M | -$49.5M | -$29.9M | -$9.7M |
| Operating cash flow | -$18.5M | -$21.3M | -$30.2M | -$39.0M | -$34.6M |
| Free cash flow | -$18.6M | -$21.3M | -$30.5M | -$44.2M | -$36.0M |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M |
| Total liabilities | $35.7M | $36.2M | $39.0M | $41.3M | $50.5M |
| Stockholders' equity | -$17.6M | -$8.9M | $13.4M | $3.2M | $12.6M |
| Cash and investments | $5.2M | $12.2M | $35.0M | $23.3M | $50.3M |
| Total debt | $21.8M | $5.1M | $5.5M | $6.2M | $5.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 20, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
All 707 Clene Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.